ATE380049T1 - Kombinationen enthaltend cgmp-pde5-hemmer. - Google Patents

Kombinationen enthaltend cgmp-pde5-hemmer.

Info

Publication number: ATE380049T1
Authority: AT; Austria
Prior art keywords: combinations containing; pde5 inhibitors; containing cgmp; cgmp; pde5
Prior art date: 1999-10-21

Application number

AT04010436T

Other languages

English (en)

Inventor

Eliot Richard Forster

Nandan Parmanand Koppiker

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-21

Filing date

2000-10-17

Publication date

2007-12-15

1999-10-21 Priority claimed from GBGB9924958.3A external-priority patent/GB9924958D0/en

2000-09-01 Priority claimed from GB0021520A external-priority patent/GB0021520D0/en

2000-10-17 Application filed by Pfizer filed Critical Pfizer

2007-12-15 Application granted granted Critical

2007-12-15 Publication of ATE380049T1 publication Critical patent/ATE380049T1/de

Links

229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title abstract 2
239000002590 phosphodiesterase V inhibitor Substances 0.000 title abstract 2
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 abstract 2
229960002870 gabapentin Drugs 0.000 abstract 1
201000001119 neuropathy Diseases 0.000 abstract 1
230000007823 neuropathy Effects 0.000 abstract 1
208000033808 peripheral neuropathy Diseases 0.000 abstract 1
229960001233 pregabalin Drugs 0.000 abstract 1
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT04010436T 1999-10-21 2000-10-17 Kombinationen enthaltend cgmp-pde5-hemmer. ATE380049T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9924958.3A GB9924958D0 (en)	1999-10-21	1999-10-21	Treatment of neuropathy
GB0021520A GB0021520D0 (en)	2000-09-01	2000-09-01	Treatment of neuropathy

Publications (1)

Publication Number	Publication Date
ATE380049T1 true ATE380049T1 (de)	2007-12-15

Family

ID=26244947

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04010436T ATE380049T1 (de)	1999-10-21	2000-10-17	Kombinationen enthaltend cgmp-pde5-hemmer.

Country Status (16)

Country	Link
US (2)	US20030162782A1 (de)
EP (2)	EP1440709B1 (de)
JP (2)	JP2001122803A (de)
KR (1)	KR20010051181A (de)
AT (1)	ATE380049T1 (de)
AU (1)	AU781550B2 (de)
CA (1)	CA2323839C (de)
CO (1)	CO5271711A1 (de)
CY (1)	CY1107285T1 (de)
DE (1)	DE60037347T2 (de)
DK (1)	DK1440709T3 (de)
ES (1)	ES2295726T3 (de)
HU (1)	HUP0004120A3 (de)
IL (2)	IL139073A0 (de)
PE (1)	PE20010754A1 (de)
PT (1)	PT1440709E (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2406947A1 (en) *	2000-04-19	2001-10-25	Johns Hopkins University	Methods for prevention and treatment of gastrointestinal disorders
FR2809623B1 (fr) *	2000-06-05	2003-09-05	Sanjuan Benito Arranz	Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives)
DE10135815A1 (de) *	2001-07-23	2003-02-06	Bayer Ag	Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
EP1575916B1 (de)	2001-08-31	2013-05-22	The Rockefeller University	Phosphodiesteraseaktivität und regulation der durch phosphodiesterase-1-b vermittelten signalvermittlung im hirn
GB0129274D0 (en) *	2001-12-06	2002-01-23	Pfizer Ltd	Novel kit
WO2003056899A2 (en)	2002-01-04	2003-07-17	Henry Ford Health System	Nitric oxide donors for treatment of disease and injury
US7419981B2 (en)	2002-08-15	2008-09-02	Pfizer Inc.	Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0219024D0 (en) *	2002-08-15	2002-09-25	Pfizer Ltd	Synergistic combinations
US7659305B2 (en)	2002-10-31	2010-02-09	Pfizer Inc.	Therapeutic proline derivatives
WO2004054560A1 (en) *	2002-12-13	2004-07-01	Warner-Lambert Company Llc	Alpha-2-delta ligand to treat lower urinary tract symptoms
DK1619180T3 (da)	2003-04-23	2010-03-29	Japan Tobacco Inc	CaSR-antagonist
DE10325813B4 (de)	2003-06-06	2007-12-20	Universitätsklinikum Freiburg	Prophylaxe und/oder Therapie bei der portalen Hypertonie
CA2557792C (en)	2004-03-05	2012-12-18	Altana Pharma Ag	Novel use for pde5 inhibitors
US8273750B2 (en)	2005-06-06	2012-09-25	Takeda Pharmaceutical Company Limited	Organic compounds
EP1919287A4 (de) *	2005-08-23	2010-04-28	Intra Cellular Therapies Inc	Organische verbindungen zur behandlung einer verringerten dopamin-rezeptorsignalisierungs-aktivität
JP5453086B2 (ja) *	2006-06-06	2014-03-26	イントラ−セルラー・セラピーズ・インコーポレイテッド	有機化合物
JP2010509399A (ja) *	2006-11-13	2010-03-25	イントラ−セルラー・セラピーズ・インコーポレイテッド	有機化合物
US9006258B2 (en)	2006-12-05	2015-04-14	Intra-Cellular Therapies, Inc.	Method of treating female sexual dysfunction with a PDE1 inhibitor
US7638541B2 (en)	2006-12-28	2009-12-29	Metabolex Inc.	5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008131256A1 (en) *	2007-04-19	2008-10-30	Trinity Laboratories Inc.	Improved treatments for premature ejaculation in humans
AU2008279447A1 (en) *	2007-07-19	2009-01-29	Metabolex, Inc.	N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
ES2588238T3 (es) *	2007-12-06	2016-10-31	Intra-Cellular Therapies, Inc.	Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
AU2008335811B2 (en)	2007-12-06	2012-05-17	Intra-Cellular Therapies, Inc.	Organic compounds
JP5989993B2 (ja)	2008-12-06	2016-09-07	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
CN102231953A (zh)	2008-12-06	2011-11-02	细胞内治疗公司	有机化合物
AU2009322904A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
KR20110098732A (ko)	2008-12-06	2011-09-01	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
MX2011005936A (es) *	2008-12-06	2011-12-16	Intra Cellular Therapies Inc	Compuestos organicos.
WO2010065147A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
JP2012518685A (ja)	2009-02-25	2012-08-16	イントラ−セルラー・セラピーズ・インコーポレイテッド	眼障害のためのｐｄｅ１阻害剤
US9468637B2 (en)	2009-05-13	2016-10-18	Intra-Cellular Therapies, Inc.	Organic compounds
SG178279A1 (en)	2009-08-05	2012-03-29	Intra Cellular Therapies Inc	Novel regulatory proteins and inhibitors
US8410127B2 (en)	2009-10-01	2013-04-02	Metabolex, Inc.	Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US20130065936A1 (en) *	2010-05-14	2013-03-14	The Regents Of The University Of California	Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors
US9763948B2 (en)	2010-05-31	2017-09-19	Intra-Cellular Therapies, Inc.	PDE1 inhibitory compounds and methods
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
WO2011153135A1 (en)	2010-05-31	2011-12-08	Intra-Cellular Therapies, Inc.	Organic compounds
US9434730B2 (en)	2010-05-31	2016-09-06	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
CA2802047C (en) *	2010-06-07	2019-05-07	Novadel Pharma Inc.	Oral spray formulations and methods for administration of sildenafil
CN109674753A (zh)	2010-06-23	2019-04-26	希玛贝治疗股份有限公司	固态分散体
EP2717877B1 (de)	2011-06-10	2017-11-08	Intra-Cellular Therapies, Inc.	Organische verbindungen
CN102276511A (zh) *	2011-06-20	2011-12-14	兰州博实生化科技有限责任公司	1-叔丁氧羰基-3-碘氮杂环丁烷的合成方法
US8449565B2 (en)	2011-07-21	2013-05-28	Francis Duhay	Approaches to venous occlusion for embolus management
US9801882B2 (en)	2013-02-17	2017-10-31	Intra-Cellular Therapies, Inc.	Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
US9545406B2 (en)	2013-03-15	2017-01-17	Intra-Cellular Therapies, Inc.	Method of treating a CNS injury with a PDE1 inhibitor
CA2906640C (en)	2013-03-15	2021-07-20	Intra-Cellular Therapies, Inc.	Substituted imidazo-[1,2-a]pyrazolo[4.3-e]pyrimidin-4[5h]-one compounds and pharmaceutical compositions and use therof as pde1 inhibitors
RU2549459C2 (ru) *	2013-08-20	2015-04-27	Константин Александрович Корейба	Способ лечения нейропатических трофических язв при синдроме диабетической стопы
EP3091983B1 (de)	2014-01-08	2019-10-02	Intra-Cellular Therapies, Inc.	Pharmazeutische zusammensetzungen enthaltend einen pde-1-hemmer und einen pde-2-hemmer
WO2015196186A1 (en)	2014-06-20	2015-12-23	Intra-Cellular Therapies, Inc.	Organic compounds
US9546175B2 (en)	2014-08-07	2017-01-17	Intra-Cellular Therapies, Inc.	Organic compounds
US10285992B2 (en)	2014-08-07	2019-05-14	Intra-Cellular Therapies, Inc.	Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
WO2016022893A1 (en)	2014-08-07	2016-02-11	Intra-Cellular Therapies, Inc.	Organic compounds
BR112017005533B1 (pt)	2014-09-17	2023-10-10	Intra-Cellular Therapies, Inc	Compostos inibidores de fosfodiesterase 1 (pde1), composição farmacêutica que compreende os ditos compostos e usos dos mesmos no tratamento de uma doença, distúrbio, e/ou lesão do snc e no tratamento e/ou na profilaxia de uma doença, distúrbio e/ou lesão do snp
CN107205993B (zh)	2014-12-06	2021-03-09	细胞内治疗公司	有机化合物
US10300064B2 (en)	2014-12-06	2019-05-28	Intra-Cellular Therapies, Inc.	Organic compounds
US10813894B2 (en)	2015-02-20	2020-10-27	The Regents Of The University Of California	Methods of inhibiting pain
EP3436083A4 (de)	2016-03-28	2019-11-27	Intra-Cellular Therapies, Inc.	Neuartige zusammensetzungen und verfahren
AU2017305392A1 (en)	2016-08-03	2019-02-21	Cymabay Therapeutics, Inc.	Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
UA125650C2 (uk)	2016-09-09	2022-05-11	Інсайт Корпорейшн	Регулятори нрk1 на основі похідних піразолопіридину та їх застосування для лікування раку
WO2018049214A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
TW201811799A (zh)	2016-09-09	2018-04-01	美商英塞特公司	吡唑并嘧啶化合物及其用途
WO2018049417A1 (en)	2016-09-12	2018-03-15	Intra-Cellular Therapies, Inc.	Novel uses
US20180228786A1 (en)	2017-02-15	2018-08-16	Incyte Corporation	Pyrazolopyridine compounds and uses thereof
US10722495B2 (en)	2017-09-08	2020-07-28	Incyte Corporation	Cyanoindazole compounds and uses thereof
MX2017016930A (es) *	2017-12-19	2019-06-20	Malesil Research & Tech Llc	Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico.
JP7401442B2 (ja)	2018-01-31	2023-12-19	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規使用
US10745388B2 (en)	2018-02-20	2020-08-18	Incyte Corporation	Indazole compounds and uses thereof
WO2019164847A1 (en)	2018-02-20	2019-08-29	Incyte Corporation	Indazole compounds and uses thereof
US10800761B2 (en)	2018-02-20	2020-10-13	Incyte Corporation	Carboxamide compounds and uses thereof
US11299473B2 (en)	2018-04-13	2022-04-12	Incyte Corporation	Benzimidazole and indole compounds and uses thereof
US10899755B2 (en)	2018-08-08	2021-01-26	Incyte Corporation	Benzothiazole compounds and uses thereof
ES2973117T3 (es)	2018-09-25	2024-06-18	Incyte Corp	Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
MX2022001562A (es)	2019-08-06	2022-04-26	Incyte Corp	Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1).
EP4025202A4 (de)	2019-09-03	2023-08-02	Intra-Cellular Therapies, Inc.	Neuartige verbindungen
US12364695B2 (en)	2020-06-02	2025-07-22	Intra-Cellular Therapies, Inc.	Methods of treating inflammatory disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT100905A (pt) *	1991-09-30	1994-02-28	Eisai Co Ltd	Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
AU722514B2 (en) *	1995-12-28	2000-08-03	Fujisawa Pharmaceutical Co., Ltd.	Benzimidazole derivatives
IL126999A (en) *	1996-07-24	2002-03-10	Warner Lambert Co	Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
US6127418A (en) *	1997-08-20	2000-10-03	Warner-Lambert Company	GABA analogs to prevent and treat gastrointestinal damage
HRP20000712A2 (en) *	1998-04-20	2001-06-30	Pfizer	PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
US6331171B1 (en) *	1998-06-04	2001-12-18	Alcon Laboratories, Inc.	Tip for a liquefracture handpiece
GB9823101D0 (en) *	1998-10-23	1998-12-16	Pfizer Ltd	Pharmaceutically active compounds
EP1123296B1 (de) *	1998-10-23	2003-09-17	Pfizer Limited	Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen
GB9823103D0 (en) *	1998-10-23	1998-12-16	Pfizer Ltd	Pharmaceutically active compounds
US6453237B1 (en) *	1999-04-23	2002-09-17	Global Locate, Inc.	Method and apparatus for locating and providing services to mobile devices
US6411892B1 (en) *	2000-07-13	2002-06-25	Global Locate, Inc.	Method and apparatus for locating mobile receivers using a wide area reference network for propagating ephemeris
IL137429A0 (en) *	1999-07-28	2001-07-24	Pfizer Prod Inc	Methods and compsitions for treating diseases and conditions of the eye
ES2272297T3 (es) *	1999-10-12	2007-05-01	Lilly Icos Llc	Medicamento destinado al tratamiento de neuropatias.
US7196660B2 (en) *	2000-11-17	2007-03-27	Global Locate, Inc	Method and system for determining time in a satellite positioning system
US6560534B2 (en) *	2001-06-06	2003-05-06	Global Locate, Inc.	Method and apparatus for distributing satellite tracking information

2000
- 2000-10-16 IL IL13907300A patent/IL139073A0/xx unknown
- 2000-10-16 IL IL152925A patent/IL152925A/en not_active IP Right Cessation
- 2000-10-17 DE DE60037347T patent/DE60037347T2/de not_active Expired - Fee Related
- 2000-10-17 AT AT04010436T patent/ATE380049T1/de not_active IP Right Cessation
- 2000-10-17 PT PT04010436T patent/PT1440709E/pt unknown
- 2000-10-17 EP EP04010436A patent/EP1440709B1/de not_active Expired - Lifetime
- 2000-10-17 EP EP00309129A patent/EP1129706A3/de not_active Withdrawn
- 2000-10-17 DK DK04010436T patent/DK1440709T3/da active
- 2000-10-17 ES ES04010436T patent/ES2295726T3/es not_active Expired - Lifetime
- 2000-10-19 CA CA002323839A patent/CA2323839C/en not_active Expired - Fee Related
- 2000-10-20 PE PE2000001133A patent/PE20010754A1/es not_active Application Discontinuation
- 2000-10-20 HU HU0004120A patent/HUP0004120A3/hu unknown
- 2000-10-20 AU AU66650/00A patent/AU781550B2/en not_active Withdrawn - After Issue
- 2000-10-20 CO CO00080163A patent/CO5271711A1/es not_active Application Discontinuation
- 2000-10-21 KR KR1020000062129A patent/KR20010051181A/ko not_active Ceased
- 2000-10-23 JP JP2000322510A patent/JP2001122803A/ja active Pending
2002
- 2002-07-26 US US10/206,615 patent/US20030162782A1/en not_active Abandoned
- 2002-10-10 JP JP2002297617A patent/JP2003119131A/ja active Pending
2003
- 2003-12-10 US US10/731,905 patent/US20040122010A1/en not_active Abandoned
2008
- 2008-02-18 CY CY20081100193T patent/CY1107285T1/el unknown

Also Published As

Publication number	Publication date
DE60037347D1 (de)	2008-01-17
CO5271711A1 (es)	2003-04-30
CY1107285T1 (el)	2012-11-21
EP1440709A3 (de)	2004-12-08
PT1440709E (pt)	2008-02-06
DE60037347T2 (de)	2008-11-27
IL139073A0 (en)	2001-11-25
CA2323839C (en)	2008-03-18
EP1129706A3 (de)	2002-01-02
HU0004120D0 (de)	2001-01-29
EP1129706A2 (de)	2001-09-05
JP2001122803A (ja)	2001-05-08
AU6665000A (en)	2001-04-26
AU781550B2 (en)	2005-05-26
DK1440709T3 (da)	2008-03-17
EP1440709B1 (de)	2007-12-05
US20030162782A1 (en)	2003-08-28
PE20010754A1 (es)	2001-07-18
KR20010051181A (ko)	2001-06-25
JP2003119131A (ja)	2003-04-23
CA2323839A1 (en)	2001-04-21
US20040122010A1 (en)	2004-06-24
HUP0004120A2 (hu)	2002-11-28
EP1440709A2 (de)	2004-07-28
IL152925A (en)	2010-04-15
HUP0004120A3 (en)	2003-11-28
ES2295726T3 (es)	2008-04-16

Legal Events

Date

Code

Title

Description

2008-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1440709

Country of ref document: EP

2010-07-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE380049T1 (de)	2007-12-15	Kombinationen enthaltend cgmp-pde5-hemmer.
BR0108750A (pt)	2002-12-24	Variantes da xilanase que apresentam sensibilidade alterada para inibidores da xilanase
MXPA04002382A (es)	2004-05-31	Combinaciones de herbicidas y antidotos.
ECSP034600A (es)	2003-06-25	Compuestos de lactama
GB2379798B (en)	2003-07-30	Light emitting diode and method for manufacturing the same
ZA9811595B (en)	2000-06-19	Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors.
WO2003080566A3 (en)	2003-12-11	Hif hydroxylase inhibitors
BR0102059B1 (pt)	2009-05-05	segmento retentor para conjunto turbilhonador.
BR0110143A (pt)	2005-01-11	Derivados de ácido heptenóico de 2-amino-5,6 halogenado úteis como inibidores de sintase de óxido nìtrico
DK1273299T3 (da)	2006-02-06	Minoxidilinindeholdende praparater
ITTO20021024A1 (it)	2003-06-11	Trattamento di superficie per componenti ferrosi.
GB0011358D0 (en)	2000-06-28	Novel use
EP1262556A3 (de)	2004-09-29	Antimikrobielle Peptide und Verfahren zu ihrer Identifizierung und Verwendung
BR0204620B1 (pt)	2013-02-19	processo para o tratamento de condensados que contÊm compostos.
PT941975E (pt)	2002-06-28	Cimento para injeccao contendo inibidores de corrosao
NZ320259A (en)	1999-06-29	Deodorizing preparations containing cationic biopolymers, aluminium hydrochlorate and esterase inhibitors
FI20031191A7 (fi)	2003-08-25	Monoamiinin takaisinoton estäjä
EA200601466A1 (ru)	2006-12-29	Новые комбинации противорвотного агента и ингибитора энкефалиназы
MY138266A (en)	2009-05-29	Treatment of neuropathy
DK1188681T3 (da)	2005-03-14	Beskyttelsesemballage til en cylindrisk genstand, forsynet med et fastgörelsesmiddel
MY140504A (en)	2009-12-31	Statin-mmp inhibitor combinations
BR0210678A (pt)	2004-09-21	Carbamatos de 2-heterocìclicos-1,2-etanodióis
PL1641447T3 (pl)	2009-04-30	Sposób oczyszczania prawastatyny
GB0113920D0 (en)	2001-08-01	Composition
WO1999066609A3 (de)	2000-01-27	Lichtquelle, mit einem ein gas einschliessenden hohlraum